Merck

MRK · NYSE

$148.30+$4.67 (+3.25%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $143.63

Latest news

NewsOct 20, 10:49 AM ETVandana Singh
Merck Discontinues Bacterial Infection Drug in Europe
NewsOct 19, 8:38 AM ETVandana Singh
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
NewsOct 15, 2:15 PM ETErica Kollmann
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
NewsOct 14, 11:39 AM ETPiero Cingari
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
NewsOct 13, 12:06 PM ETVandana Singh
Why Is BioNTech Stock Falling Tuesday?
Press releaseOct 13, 7:02 AM ETBusiness Wire
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Press releaseOct 13, 6:45 AM ETBusiness Wire
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
NewsOct 12, 9:00 AM ETNamrata Sen
Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’
NewsOct 12, 5:12 AM ETAnanya Gairola
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Press releaseOct 10, 6:10 PM ETBusiness Wire
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
NewsOct 10, 1:54 AM ETTanya Rawat
John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist
NewsOct 9, 3:11 PM ETNeeraj Jain
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
NewsOct 8, 5:59 AM ET
'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg
NewsOct 7, 1:44 PM ETVandana Singh
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Press releaseOct 7, 9:59 AM ETGlobe Newswire
2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
NewsOct 6, 12:27 AM ETMohd Haider
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
NewsOct 5, 8:55 AM ETVandana Singh
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Press releaseOct 1, 6:45 AM ETBusiness Wire
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
NewsSep 30, 2:29 PM ETVandana Singh
Merck Says Investigational Skin Therapy Shows Potential
NewsSep 30, 1:58 PM ETVandana Singh
What's Going On With Moderna Stock on Wednesday?
NewsSep 30, 8:18 AM ET
Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16
Press releaseSep 30, 8:15 AM ETBusiness Wire
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
NewsSep 29, 6:57 AM ETTanya Rawat
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
NewsSep 28, 12:44 PM ETVandana Singh
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Press releaseSep 28, 8:00 AM ETPRNewswire
CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Press releaseSep 28, 6:45 AM ETBusiness Wire
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Press releaseSep 25, 4:30 PM ETBusiness Wire
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
NewsSep 25, 4:02 PM ETPiero Cingari
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
NewsSep 25, 6:51 AM ET
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
Press releaseSep 25, 6:45 AM ETBusiness Wire
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
NewsSep 24, 10:54 PM ETMohd Haider
Why is Moderna (MRNA) Stock Trending After Hours?
NewsSep 17, 12:59 PM ETSurbhi Jain
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
NewsSep 8, 11:27 AM ETChandrima Sanyal
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back
NewsAug 27, 9:31 AM ETVandana Singh
Moderna Borrows $2 Billion To Expand Oncology Business
NewsAug 25, 3:31 PM ETDaragh Thomas
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
NewsAug 22, 8:01 AM ET
Benzinga Bulls and Bears: Ross, Moderna, Webull
NewsAug 21, 6:00 PM ETRishabh Mishra
MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
NewsApr 27, 12:21 PM ETChris Katje
The Dow Jones Earnings Showdown: 11 Blue‑Chips Step Up This Week
NewsFeb 27, 2:00 PM ET
A Look Into Merck & Co Inc's Price Over Earnings
NewsJan 2, 5:06 PM ETChris Katje
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
NewsDec 12, 11:42 AM ETErica Kollmann
To Every Stock There Is A Season: Traders Turn, Turn, Turn Out Of Tech
NewsDec 1, 12:00 PM ET
A Look Into Merck & Co Inc's Price Over Earnings
NewsSep 22, 11:00 AM ET
Price Over Earnings Overview: Merck & Co
NewsJul 28, 8:12 AM ETAvi Kapoor
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
NewsJul 24, 10:01 AM ET
P/E Ratio Insights for Merck & Co
NewsJul 1, 12:34 PM ETChris Katje
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Merck Discontinues Bacterial Infection Drug in Europe

Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks

Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today

Why Is BioNTech Stock Falling Tuesday?

Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors

Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026

Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’

Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope

Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety

Vaxcyte Stock Hits New 52-Week High - Here’s Why

Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29

Merck Says Investigational Skin Therapy Shows Potential

What's Going On With Moderna Stock on Wednesday?

Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab

Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug

CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street

Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Why is Moderna (MRNA) Stock Trending After Hours?

Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part

Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back

Moderna Borrows $2 Billion To Expand Oncology Business

Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?

Benzinga Bulls and Bears: Ross, Moderna, Webull

MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week

The Dow Jones Earnings Showdown: 11 Blue‑Chips Step Up This Week

A Look Into Merck & Co Inc's Price Over Earnings

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

To Every Stock There Is A Season: Traders Turn, Turn, Turn Out Of Tech

A Look Into Merck & Co Inc's Price Over Earnings

Price Over Earnings Overview: Merck & Co

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

P/E Ratio Insights for Merck & Co

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%